Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
A phase 2 clinical trial for the efficacy and safety of low dose Temozolomide plus metformin
as combination chemotherapy compared with low dose Temozolomide plus placebo in patient with
recurrent or refractory Glioblastoma
Phase:
Phase 2
Details
Lead Sponsor:
Yong-Kil Hong
Collaborators:
Ajou University School of Medicine Asan Medical Center Chonnam National University Hospital Incheon St.Mary's Hospital Konkuk University Hospital National Cancer Center, Korea Saint Vincent's Hospital, Korea Samsung Medical Center Seoul National University Bundang Hospital Seoul National University Hospital Seoul St. Mary's Hospital Severance Hospital